HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CARB

This article was originally published in The Rose Sheet

Executive Summary

The California Air Resources Board released an initial statement of reasons for its Proposed Amendments to the California Consumer Products Regulation and the Aerosol Coatings Regulation Sept. 29. The agency plans to present the proposed amendment to the Air Resources Board during a Nov. 16-17 meeting at the California EPA headquarters in San Francisco. The proposed 2006 amendments would set 18 new volatile organic compound limits that would affect 15 product categories and reduce VOC emissions by 10.6 tons per day statewide by 2008 and 11.5 tons per day by 2010. Most beauty-related categories will be addressed during a March 22 hearing (1"The Rose Sheet" Sept. 24, 2006, p. 8)...

You may also be interested in...



CARB Postpones Board Review Of MIR Limits In Hair Spray, Nail Coatings

The California Air Resources Board will defer its review of maximum incremental reactivity limits for hair spray and nail coatings until a March 22 board hearing, the agency announced during a Sept. 14 public workshop

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.

 

ATMPs Put EU Cross-Border Healthcare On The Map

Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.

UsernamePublicRestriction

Register

RS014257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel